Compared to non-COVID-19 patients, COVID-19 patients displayed a unique plasma signature of coagulopathy-associated biomarkers with significantly higher plasma concentrations of soluble vascular cell adhesion molecule 1 (sVCAM1) (5739 ± 3293 vs. 3700 ± 2124 ng/ml; p = 0.009), but lower levels of D-dimers, von Willebrand factor A2 (vWF-A2), soluble intercellular adhesion molecule 1 (sICAM1), soluble triggering receptor expressed on myeloid cells 1 (sTREM1), vascular endothelial growth factor (VEGF), and P-selectin (all with p < 0.05). The gene discussed is VEGFA; the disease is blood coagulation disease.